ZNG1E: A Potential Drug Target and Biomarker for the Treatment of Cancer

Target Name: ZNG1E

NCBI ID: G220869

ZNG1E

ZNG1E: A Potential Drug Target and Biomarker for the Treatment of Cancer

Abstract:

ZNG1E (Cobalamin synthase W domain-containing protein 3) is a protein that has been identified as a potential drug target and biomarker for the treatment of cancer. Its unique structure and function make it an attractive target for drug development, and its expression has been found to be elevated in various types of cancer. Further research is needed to understand the full potential of ZNG1E as a drug and to explore its potential as a biomarker for cancer diagnosis and treatment.

Introduction:

Cancer is a leading cause of death worldwide, and its incidence is increasing in many countries. The development of new treatments for cancer has become a major focus of research in the past few decades. One of the promising areas of research is the discovery of new protein targets for cancer treatment. These targets can be used to develop new drugs or to enhance the effectiveness of existing drugs. One of the promising protein targets that is being explored is ZNG1E (Cobalamin synthase W domain-containing protein 3).

ZNG1E: A Potential Drug Target:

ZNG1E is a protein that is expressed in various tissues and cells of the body. It is located in the endoplasmic reticulum and is involved in the synthesis of cobalamin, also known as vitamin B12. This vitamin is essential for the development and maintenance of healthy nervous muscles, red blood cells, and DNA. ZNG1E is also involved in the regulation of cellular processes, including cell division, DNA replication, and protein synthesis.

Recent studies have shown that ZNG1E is involved in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. It has also been found to be overexpressed in these types of cancer, which means that its expression is higher than in normal cells. This suggests that targeting ZNG1E may be an effective way to treat cancer.

ZNG1E: A Potential Biomarker:

In addition to its potential as a drug target, ZNG1E has also been identified as a potential biomarker for cancer. Its expression has been found to be elevated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that ZNG1E may be a useful biomarker for the diagnosis and treatment of cancer.

One of the challenges in the development of biomarkers for cancer is the difficulty in predicting which patients will respond to a particular treatment. By using ZNG1E as a biomarker, researchers can gain insights into the effectiveness of a particular treatment on a patient's cancer cells. This information can be used to improve the accuracy of cancer diagnosis and to tailor treatments to individual patients.

Conclusion:

ZNG1E is a protein that has been identified as a potential drug target and biomarker for the treatment of cancer. Its unique structure and function make it an attractive target for drug development, and its expression has been found to be elevated in various types of cancer. Further research is needed to understand the full potential of ZNG1E as a drug and to explore its potential as a biomarker for cancer diagnosis and treatment.

FAQs:

Q: What is ZNG1E?
A: ZNG1E (Cobalamin synthase W domain-containing protein 3) is a protein that is expressed in various tissues and cells of the body.

Q: What is its function?
A: ZNG1E is involved in the synthesis of cobalamin, also known as vitamin B12. It is also involved in the regulation of cellular processes, including cell division, DNA replication, and protein synthesis.

Q: Is ZNG1E a potential drug target?
A: ZNG1E is a potential drug target for the treatment of cancer. Its unique structure and function make it an attractive target for drug development.

Q: Is ZNG1E a potential biomarker for cancer?
A: ZNG1E has been identified as a potential biomarker for cancer. Its expression has been found to be elevated in various types of cancer.

Protein Name: Zn Regulated GTPase Metalloprotein Activator 1E

Functions: Zinc chaperone that directly transfers zinc cofactor to target metalloproteins, thereby activating them. Catalyzes zinc insertion into the active site of methionine aminopeptidase METAP1, which function to cleave the initiator methionine from polypeptides during or after protein translation. Mechanistically, the N-terminal psi-PxLVp motif binds to the C6H2-type zinc finger of inactive form of METAP1. After formation of the docked complex, zinc is transferred from the CXCC motif in the GTPase domain of ZNG1C to the zinc binding site in the peptidase domain of METAP1 in a process requiring GTP hydrolysis. GTP/GDP exchange is required for release of active METAP1

The "ZNG1E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNG1E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets